Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

A phase 2 trial of CD24Fc for prevention of graft-versus-host disease

Blood (2024) 143 (1): 21–31.

https://doi.org/10.1182/blood.2023020250

Published: 2024

Includes: Supplemental data

Journal Articles

Mgta-117, an Anti-CD117 Antibody-Drug Conjugated with Amanitin, in Participants with Relapsed/Refractory Adult Acute Myeloid Leukemia (AML) and Myelodysplasia with Excess Blasts (MDS-EB): Safety, Pharmacokinetics and Pharmacodynamics Initial Findings from a Phase 1/2 Study

Peter Westervelt, Partow Kebriaei, Mark Juckett, Andrew S. Artz, Onyee Chan, Philip L. McCarthy, Sherif S Farag, Anurag K. Singh, Eytan Stein, Jeffrey Humphrey, William Baeder, Ji Hyun Lee, Alison Occhiuti, Jeanie Tang, David Santos, Kirk Bertelsen, Balaji Mahender, Nicole Henry, Shawn Rose

Blood (2022) 140 (Supplement 1): 2117–2119.

https://doi.org/10.1182/blood-2022-162406

Published: 2022

Journal Articles

The in Vitro and In Vivo Effects of DPP-4 Inhibition with Sitagliptin, Alone and in Combination with Bortezomib, on T Cell Activation: Rationale for GvHD Prevention

Shuhong Zhang, Xingkui Xue, Maggie Granatir, George E. Sandusky, Sheng Liu, Jun Wan, Xiaoling Xuei, Yunlong Liu, Anthony L. Sinn, Karen E. Pollok, Sherif S Farag

Blood (2022) 140 (Supplement 1): 10204–10205.

https://doi.org/10.1182/blood-2022-163679

Published: 2022

Journal Articles

The Pre-Existing T Cell Landscape Is Associated with Response to High Dose Melphalan and Autologous Stem Cell Transplant in Multiple Myeloma

Mohammad Issam Abu Zaid, Parvathi Sudha, Travis S Johnson, Vivek S. Chopra, Cedric E. Dos Santos, Michael Nixon, Attaya Suvannasankha, Sherif S Farag, Kelvin P. Lee, Rafat Abonour, Brian A. Walker

Blood (2022) 140 (Supplement 1): 9919–9920.

https://doi.org/10.1182/blood-2022-167619

Published: 2022

Journal Articles

Impacts of Total Body Irradiation in Allogeneic Umbilical Cord Blood Hematopoietic Stem Cell Transplantation

Jeffrey J. Pu, Kristin N. Berger, Hao Wang, Wei Fu, Elizabeth L Miller, Larisa Broglie, Heiko Konig, Frederick Goldman, Julie-An Talano, Sherif S. Farag, Melanie Comito

Blood (2021) 138 (Supplement 1): 4852.

https://doi.org/10.1182/blood-2021-152893

Published: 2021

Journal Articles

Pre-Transplant M Protein Level Predicts Minimal Residual Disease Status after Autologous Stem Cell Transplantation in Multiple Myeloma

Zachary S Meyer, Mohamed Manaa, Yan Han, Magdalena Czader, Attaya Suvannasankha, Rafat Abonour, Sherif S Farag, Melissa Stanley, Mohammad Issam Abu Zaid

Blood (2021) 138 (Supplement 1): 4903.

https://doi.org/10.1182/blood-2021-149595

Published: 2021

Journal Articles

Assessment of ST2 for risk of death following graft-versus-host disease in pediatric and adult age groups

Courtney M. Rowan, Francis Pike, Kenneth R. Cooke, Robert Krance, Paul A. Carpenter, Christine Duncan, David A. Jacobsohn, Catherine M. Bollard, Conrad Russell Y. Cruz, Abhijeet Malatpure, Sherif S. Farag, Jamie Renbarger, Hao Liu, Giorgos Bakoyannis, Samir Hanash, Sophie Paczesny

Blood (2020) 135 (17): 1428–1437.

https://doi.org/10.1182/blood.2019002334

Published: 2020

Includes: Supplemental data

Journal Articles

Inhibition of PIM Kinases Mitigates DNA Repair Responses Following Anthracycline-Induced DNA Damage and Enhances the Anti-Tumor Activity of Doxorubicin Against Lymphoma Cells

Jeffrey D. Altenburg, PhD, Shuhong Zhang, PhD, Michelle Grimard, Xingkui Xue, MD PhD, Sherif S Farag, MD PhD

Blood (2014) 124 (21): 4505.

https://doi.org/10.1182/blood.V124.21.4505.4505

Published: 2014

Journal Articles

A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma

Don M. Benson, Jr, Craig C. Hofmeister, Swaminathan Padmanabhan, Attaya Suvannasankha, Sundar Jagannath, Rafat Abonour, Courtney Bakan, Pascale Andre, Yvonne Efebera, Jérôme Tiollier, Michael A. Caligiuri, Sherif S. Farag

Blood (2012) 120 (22): 4324–4333.

https://doi.org/10.1182/blood-2012-06-438028

Published: 2012

Journal Articles

IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect

Don M. Benson, Jr, Courtney E. Bakan, Shuhong Zhang, Shauna M. Collins, Jing Liang, Shivani Srivastava, Craig C. Hofmeister, Yvonne Efebera, Pascale Andre, Francois Romagne, Mathieu Bléry, Cécile Bonnafous, Jianying Zhang, David Clever, Michael A. Caligiuri, Sherif S. Farag

Blood (2011) 118 (24): 6387–6391.

https://doi.org/10.1182/blood-2011-06-360255

Published: 2011

Includes: Supplemental data

Journal Articles

Synergistic Activity of Bendamustine in Combination with Doxorubicin and Bortezomib in Multiple Myeloma Cells

Shuhong Zhang, PhD, Xiaojing Wang, PhD, Li Chen, Jing Liang, Attaya Suvannasankha, MD, Rafat Abonour, MD, Sherif S Farag, MD, PhD

Blood (2008) 112 (11): 5171.

https://doi.org/10.1182/blood.V112.11.5171.5171

Published: 2008

Journal Articles

The Novel Aurora Kinase Inhibitor ENMD-2076 Has Potent Single Agent Activity against Multiple Myeloma (MM) in Vitro and in Vivo , and Shows Synergistic Activity in Combination with Lenalidomide

Xiaojing Wang, PhD, Anthony L. Sinn, Attaya Suvannasankha, MD, Colin D. Crean, Li Chen, MD, Shuhong Zhang, PhD, Jing Liang, MD, Genglin Zhang, Karen E. Pollok, PhD, Rafat Abonour, MD, Carolyn Sidor, MD, Mark R. Bray, PhD, Sherif S. Farag, MD, PhD

Blood (2008) 112 (11): 3660.

https://doi.org/10.1182/blood.V112.11.3660.3660

Published: 2008

Journal Articles

Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT

Jeffery S. Miller, Sarah Cooley, Peter Parham, Sherif S. Farag, Michael R. Verneris, Karina L. McQueen, Lisbeth A. Guethlein, Elizabeth A. Trachtenberg, Michael Haagenson, Mary M. Horowitz, John P. Klein, Daniel J. Weisdorf

Blood (2007) 109 (11): 5058–5061.

https://doi.org/10.1182/blood-2007-01-065383

Published: 2007

Journal Articles

OSU03012, a Novel Celecoxib Derivative, Induces Apoptosis in Multiple Myeloma Cells Independently of Caspase Activation.

Shuhong Zhang, PhD, Valerie L. White, Amy Johnson, PhD, Ching-Shih Chen, PhD, Sherif S. Farag, MD, PhD

Blood (2006) 108 (11): 5075.

https://doi.org/10.1182/blood.V108.11.5075.5075

Published: 2006

Journal Articles

OSU-HDAC42, a Novel Histone Deacetylase Inhibitor, Induces Apoptosis in a Caspase-Dependent Manner and Induces p 21WAF1/CIP1 and p16 Expression in Multiple Myeloma Cell Lines.

Valerie L. White, Shuhong Zhang, PhD, David Lucas, PhD, Ching-Shih Chen, PhD, Sherif S. Farag, MD, PhD

Blood (2006) 108 (11): 5078.

https://doi.org/10.1182/blood.V108.11.5078.5078

Published: 2006

Journal Articles

Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461

Sherif S. Farag, Kellie J. Archer, Krzysztof Mrózek, Amy S. Ruppert, Andrew J. Carroll, James W. Vardiman, Mark J. Pettenati, Maria R. Baer, Mazin B. Qumsiyeh, Prasad R. Koduru, Yi Ning, Robert J. Mayer, Richard M. Stone, Richard A. Larson, Clara D. Bloomfield

Blood (2006) 108 (1): 63–73.

https://doi.org/10.1182/blood-2005-11-4354

Published: 2006

Journal Articles

Flavopiridol, Fludarabine and Rituximab Is a Highly Active Regimen in Indolent B-Cell Lymphoproliferative Disorders Including Mantle Cell Lymphoma.

Thomas S. Lin, MD, PhD, Beth Fischer, RN, Mollie E. Moran, RN, CNP, Maureen M. Buckner, RN, CNP, Roshini Shank, BS, Eric H. Kraut, MD, Pierluigi Porcu, MD, Sherif S. Farag, MD, PhD, Charles F. Eisenbeis, MD, PhD, Dimitrios Colevas, MD, Michael R. Grever, MD, John C. Byrd, MD

Blood (2005) 106 (11): 944.

https://doi.org/10.1182/blood.V106.11.944.944

Published: 2005

Journal Articles

DC therapy? Let the natural killer answer

Sherif S. Farag

Blood (2005) 106 (6): 1892.

https://doi.org/10.1182/blood-2005-06-2608

Published: 2005

Journal Articles

FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia

Thomas S. Lin, Ian W. Flinn, Rama Modali, Teresa A. Lehman, Jennifer Webb, Sharon Waymer, Mollie E. Moran, Margaret S. Lucas, Sherif S. Farag, John C. Byrd

Blood (2005) 105 (1): 289–291.

https://doi.org/10.1182/blood-2004-02-0651

Published: 2005

Journal Articles

Depletion of alloreactive T cells: which cell?

Sherif S. Farag

Blood (2004) 104 (12): 3422–3423.

https://doi.org/10.1182/blood-2004-09-3476

Published: 2004

NARROW

A phase 2 trial of CD24Fc for prevention of graft-versus-host disease

Mgta-117, an Anti-CD117 Antibody-Drug Conjugated with Amanitin, in Participants with Relapsed/Refractory Adult Acute Myeloid Leukemia (AML) and Myelodysplasia with Excess Blasts (MDS-EB): Safety, Pharmacokinetics and Pharmacodynamics Initial Findings from a Phase 1/2 Study

The in Vitro and In Vivo Effects of DPP-4 Inhibition with Sitagliptin, Alone and in Combination with Bortezomib, on T Cell Activation: Rationale for GvHD Prevention

The Pre-Existing T Cell Landscape Is Associated with Response to High Dose Melphalan and Autologous Stem Cell Transplant in Multiple Myeloma

Impacts of Total Body Irradiation in Allogeneic Umbilical Cord Blood Hematopoietic Stem Cell Transplantation

Pre-Transplant M Protein Level Predicts Minimal Residual Disease Status after Autologous Stem Cell Transplantation in Multiple Myeloma

Assessment of ST2 for risk of death following graft-versus-host disease in pediatric and adult age groups

Inhibition of PIM Kinases Mitigates DNA Repair Responses Following Anthracycline-Induced DNA Damage and Enhances the Anti-Tumor Activity of Doxorubicin Against Lymphoma Cells

A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma

IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect

Synergistic Activity of Bendamustine in Combination with Doxorubicin and Bortezomib in Multiple Myeloma Cells

The Novel Aurora Kinase Inhibitor ENMD-2076 Has Potent Single Agent Activity against Multiple Myeloma (MM) in Vitro and in Vivo , and Shows Synergistic Activity in Combination with Lenalidomide

Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT

OSU03012, a Novel Celecoxib Derivative, Induces Apoptosis in Multiple Myeloma Cells Independently of Caspase Activation.

OSU-HDAC42, a Novel Histone Deacetylase Inhibitor, Induces Apoptosis in a Caspase-Dependent Manner and Induces p 21WAF1/CIP1 and p16 Expression in Multiple Myeloma Cell Lines.

Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461

Flavopiridol, Fludarabine and Rituximab Is a Highly Active Regimen in Indolent B-Cell Lymphoproliferative Disorders Including Mantle Cell Lymphoma.

DC therapy? Let the natural killer answer

FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia

Depletion of alloreactive T cells: which cell?

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only